MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, X.
Right arrow Articles by Wei, L.-N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, X.
Right arrow Articles by Wei, L.-N.

Vol. 62, Issue 4, 881-887, October 2002

Regulation of Mouse kappa  Opioid Receptor Gene Expression by Different 3'-Untranslated Regions and the Effect of Retinoic Acid

Xinli Hu, Jing Bi, Horace H. Loh, and Li-Na Wei

Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota

The mouse kappa  opioid receptor (KOR) gene uses two functional polyadenylation signals, separated by a distance of approximately 2.2 kilobases (kb) in the 3'-end of the gene. As a result, two major groups of KOR transcripts, with sizes of approximately 1.6 and 3.8 kb, respectively, are detected in mouse tissues and P19 cells. Utilization of different poly(A) of the KOR gene produces KOR transcripts of different mRNA stability, transcription efficiency, and regulatability. Retinoic acid specifically suppresses the expression of KOR transcripts using the second poly(A) in P19 cells. A putative transcriptional enhancer region is present within the second 3'-untranslated region (3'-UTR). It is concluded that alternative polyadenylation of the mouse KOR transcripts results in differential regulation of KOR expression at both transcriptional and post-transcriptional levels. A negative regulatory pathway for KOR transcription involves a putative enhancer region in its 3'-UTR. KOR mRNAs using the second poly(A) is more stable than that using the first poly(A).

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
E. Kim, A. L. Clark, A. Kiss, J. W. Hahn, R. Wesselschmidt, C. J. Coscia, and M. M. Belcheva
{micro}- and {kappa}-Opioids Induce the Differentiation of Embryonic Stem Cells to Neural Progenitors
J. Biol. Chem., November 3, 2006; 281(44): 33749 - 33760.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
N.-P. Tsai, J. Bi, H. H. Loh, and L.-N. Wei
Netrin-1 signaling regulates de novo protein synthesis of kappa opioid receptor by facilitating polysomal partition of its mRNA.
J. Neurosci., September 20, 2006; 26(38): 9743 - 9749.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Q. Wu, C. K. Hwang, S. Yao, P.-Y. Law, H. H. Loh, and L.-N. Wei
A Major Species of Mouse {micro}-opioid Receptor mRNA and Its Promoter-Dependent Functional Polyadenylation Signal
Mol. Pharmacol., August 1, 2005; 68(2): 279 - 285.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
P.-W. Lee, S. Wu, and Y.-M. Lee
Differential Expression of {micro}-Opioid Receptor Gene in CXBK and B6 Mice by Sp1
Mol. Pharmacol., December 1, 2004; 66(6): 1580 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
O. Pol, J. R. Palacio, and M. M. Puig
The Expression of {delta}- and {kappa}-Opioid Receptor Is Enhanced during Intestinal Inflammation in Mice
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 455 - 462.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics